A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection.

Abstract:

BACKGROUND:Sirolimus, a new immunosuppressive agent, has recently been approved in the United States for use in combination with cyclosporine and corticosteroids in renal allograft transplantation. Therapeutic drug monitoring (TDM) of sirolimus is advocated by the drug's manufacturer in certain patient populations. Given the known pharmacokinetic interaction of sirolimus with cyclosporine and the requirement for patient compliance, physicians may wish to monitor steady-state trough levels of this agent. Several types of analytical methods have been investigated for use in TDM of sirolimus: immunoassay, high-performance liquid chromatography with ultraviolet detection (HPLC-UV), and HPLC with mass-spectrometric detection (HPLC-MS or HPLC/MS/MS). OBJECTIVE:This review identifies analytical parameters that are critical to clinical TDM of sirolimus when HPLC-UV is used. METHODS:Extraction of sirolimus from whole blood was performed using either liquid-liquid or solid phase techniques, whereas liquid chromatography was performed on reverse-phase analytical columns. The drug was detected at its UV extinction maximum. Calculated analytical parameters were evaluated according to current industry standards. RESULTS:HPLC-UV methods for the quantification of sirolimus meet or exceed industry standards of performance for clinical TDM. Comparison of the sirolimus levels in clinical samples analyzed by both HPLC-UV and HPLC/MS/MS indicated that the methods provided similar results. CONCLUSION:HPLC-UV methods, although they use a less-sophisticated mode of detection than HPLC-MS or HPLC/MS/MS methods, provide an alternative means of performing TDM without sacrificing the analytical performance required for clinical monitoring of sirolimus.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Napoli KL

doi

10.1016/s0149-2918(00)89019-0

subject

Has Abstract

pub_date

2000-01-01 00:00:00

pages

B14-24

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(00)89019-0

journal_volume

22 Suppl B

pub_type

杂志文章
  • Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men.

    abstract:BACKGROUND:Due to Mexico's complicated socioeconomic environment, causing a high occurrence of >1 person sharing a single room, respiratory conditions are spread easily. Respiratory conditions are the main reason for consultation with a physician. The most frequent symptoms are throat soreness and cough; therefore, a n...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(03)80215-1

    authors: Villacampa J,Alcántar F,Rodríguez JM,Morales JM,Herrera J,Rosete R

    更新日期:2003-08-01 00:00:00

  • Tablet splitting of psychotropic drugs for patients with dementia: a pharmacoepidemiologic study in a Brazilian sample.

    abstract:PURPOSE:The objective of this study was to assess the frequency of tablet splitting of psychotropic drugs in a population of older adults with a diagnosis of dementia. METHODS:This retrospective, cross-sectional study examined a sample of geriatric outpatients seen at a public center specializing in the care of elderl...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2015.08.015

    authors: Mascarenhas Starling F,Medeiros-Souza P,Francisco de Camargos E,Ferreira F,Rodrigues Silva A,Homem-de-Mello M

    更新日期:2015-10-01 00:00:00

  • Sodium hyaluronate in the repair of perforations of the tympanic membrane.

    abstract::Hyaluronic acid is the most abundant mucopolysaccharide in connective tissue. Because of its high viscous elasticity, it lubricates joints and can hold cells together in the intercellular spaces in connective tissue. The administration of exogenous hyaluronic acid can increase the repair potential of damaged tissue. A...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Camarda V,Cervellini M,Pedace G,Pace M

    更新日期:1989-11-01 00:00:00

  • Management of acute coronary syndromes in patients with diabetes: implications of the FREEDOM trial.

    abstract:BACKGROUND:Diabetes mellitus (DM) is a powerful independent risk factor for multivessel, diffuse coronary artery disease (CAD). The optimal coronary revascularization strategy in DM is not clearly defined, but past trials have suggested an advantage for coronary artery bypass grafting (CABG). Recently, the Future Revas...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2013.07.427

    authors: Burgess SN,Mussap CJ,French JK

    更新日期:2013-08-01 00:00:00

  • Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.

    abstract:OBJECTIVE:These studies assessed the comparative efficacy of rofecoxib and valdecoxib in the treatment of acute postoperative dental pain. METHODS:Two randomized, double-blind, placebo-controlled, single-dose studies were conducted in patients undergoing extraction of > or =2 third molars, with > or =1 mandibular impa...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2006.07.005

    authors: Daniels SE,Desjardins PJ,Bird SR,Smugar SS,Tershakovec AM

    更新日期:2006-07-01 00:00:00

  • Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.

    abstract:BACKGROUND:Prostaglandin analogues are effective ocular hypotensive agents and are being used increasingly in the treatment of elevated intraocular pressure (IOP). These agents are typically dosed once daily. OBJECTIVES:A pilot study was conducted to evaluate the duration of travoprost's IOP-lowering efficacy up to 84...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(04)90008-2

    authors: Dubiner HB,Sircy MD,Landry T,Bergamini MV,Silver LH,Darell Turner F,Robertson S,Andrew RM,Weiner A,Przydryga J

    更新日期:2004-01-01 00:00:00

  • Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.

    abstract:BACKGROUND:PHX1149 is a dipeptidyl peptidase-4 (DPP4) inhibitor that is currently in clinical development for the treatment of type 2 diabetes mellitus. PHX1149 is a small (molecular weight = 241.16 Da), highly water-soluble (>2 g/mL), orally active molecule with a selectivity index of 15- to 319-fold relative to those...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2007.08.005

    authors: O'Farrell AM,van Vliet A,Abou Farha K,Cherrington JM,Campbell DA,Li X,Hanway D,Li J,Guler HP

    更新日期:2007-08-01 00:00:00

  • Direct Medical Costs and Utilization of Health Care Services to Treat Pneumonia in the United States: An Analysis of the 2007-2011 Medical Expenditure Panel Survey.

    abstract:PURPOSE:This study aimed to assess how pneumonia incidence, health care resource utilization, costs, and hospital length of stay differ by age category in the United States. METHODS:A retrospective cross-sectional analysis of the Medical Expenditure Panel Survey database was conducted from 2007 to 2011 for patients wi...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2015.04.013

    authors: Park H,Adeyemi AO,Rascati KL

    更新日期:2015-07-01 00:00:00

  • Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.

    abstract:BACKGROUND:Many patients with asthma require an inhaled long-acting beta(2)-agonist (LABA) in addition to an inhaled corticosteroid to adequately control their disease. OBJECTIVE:The purpose of this study was to assess the long-term tolerability of a salmeterol xinafoate/ fluticasone propionate (SFC) hydrofluoroalkane...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2007.07.021

    authors: Cowie RL,Boulet LP,Keith PK,Scott-Wilson CA,House KW,Dorinsky PM

    更新日期:2007-07-01 00:00:00

  • Quality of life of people with epilepsy in the United States.

    abstract::Health care provision in the United States is driven by the fact that most health insurance is commercial and private. This leads to the tendency to view patients as units that will produce a future cash yield. The quality of life (QOL) movement in the United States is in some ways a response to this view and has a ro...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0149-2918(98)80021-0

    authors: Leppik IE

    更新日期:1998-01-01 00:00:00

  • Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses.

    abstract:PURPOSE:Our purpose was to determine satisfaction and confidence of the Ixcellence Network training program on health care practitioners using botulinum toxin A (BoNT-A) for neurologic disorders, including spastic paresis and cervical dystonia. METHODS:The Ixcellence Network training program was designed by a scientif...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2019.09.007

    authors: Colosimo C,Bhidayasiri R,Fheodoroff K,Bhatia K,Chung TM,Landreau T,Jacinto LJ

    更新日期:2019-11-01 00:00:00

  • A review of combination therapy in patients with benign prostatic hyperplasia.

    abstract:BACKGROUND:Trials of monotherapy with alpha(1)-adrenergic-receptor antagonists (alpha(1)ARAs) and 5 alpha-reductase inhibitors (5ARIs) have found that the former drug class is effective in managing benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) and improving the maximal urinary flow rate...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0149-2918(07)80077-4

    authors: McVary KT

    更新日期:2007-03-01 00:00:00

  • Phenytoin revisited.

    abstract::Phenytoin has a wide range of pharmacologic effects other than its anticonvulsant activity. It has been the subject of more than 8,000 published papers, which include clinical reports of its usefulness in approximately 100 diseases and symptoms. In the United States the only indications for use in the official labelin...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Finkel MJ

    更新日期:1984-01-01 00:00:00

  • Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

    abstract:BACKGROUND:Treatment with interferon-beta (IFN-beta) has been related to worsening of muscle spasticity in patients with multiple sclerosis (MS). However, there are no specific data on the effects of glatiramer acetate (GA) on spasticity. OBJECTIVE:The aim of the present study was to assess the effects of GA on spasti...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clinthera.2010.06.005

    authors: Meca-Lallana JE,de Mingo-Casado P,Amorin-Díaz M,Martínez-Navarro ML,Barreiro AF

    更新日期:2010-06-01 00:00:00

  • Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the United States: a cross-sectional analysis of the national health and nutrition examination survey.

    abstract:PURPOSE:Antihypertensive drugs are prescribed to patients with chronic kidney disease (CKD) for their cardioprotective and renoprotective effects. Nationally representative information on the use of antihypertensive drugs among CKD patients is limited. The purpose of this study was to assess the utilization patterns of...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2014.11.011

    authors: Sonawane KB,Qian J,Hansen RA

    更新日期:2015-01-01 00:00:00

  • Sparfloxacin: a review.

    abstract:BACKGROUND:The continuing increase in the rate of penicillin and cephalosporin resistance among respiratory pathogens and of cross-resistance to macrolide antibiotics has led to the recommendation that fluoroquinolone antibiotics be used to treat high-risk patients with community-acquired pneumonia (CAP) and acute bact...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/S0149-2918(00)89007-4

    authors: Schentag JJ

    更新日期:2000-04-01 00:00:00

  • Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.

    abstract:PURPOSE:Although the efficacy of canagliflozin has been well established in clinical trials, research regarding its use and impact on outcomes in clinical practice has been limited by the availability of data on observations up to and beyond 6 months after the initial use of canagliflozin. The purpose of this study was...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2016.07.009

    authors: Bailey RA,Schwab P,Xu Y,Pasquale M,Renda A

    更新日期:2016-09-01 00:00:00

  • Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.

    abstract:PURPOSE:Our study evaluated adverse events of therapeutic failure (and specifically reduced duration of action) with the use of a branded product, Osmotic Release Oral System (OROS) methylphenidate, which is approved for the treatment of attention deficit/hyperactivity disorder, and a generic product (methylphenidate, ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2017.08.018

    authors: Park-Wyllie L,van Stralen J,Castillon G,Sherman SE,Almagor D

    更新日期:2017-10-01 00:00:00

  • Treatment of vaginal candidiasis in pregnant women.

    abstract::Pregnancy creates a climate favorable to the growth of Candida albicans, and this yeast often is difficult to eradicate in pregnant women. Miconazole nitrate administered intravaginally has been found to achieve comparable therapeutic and mycological cure rates in both pregnant and nonpregnant women. A number of clini...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Weisberg M

    更新日期:1986-01-01 00:00:00

  • Rosuvastatin in the management of hyperlipidemia.

    abstract:BACKGROUND:Rosuvastatin is a new statin indicated to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia, mixed dyslipidemia, and homozygous famili...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2004.09.005

    authors: Cheng JW

    更新日期:2004-09-01 00:00:00

  • A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia.

    abstract:PURPOSE:The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. METHODS:A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertens...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2017.10.013

    authors: Lee HY,Kim SY,Choi KJ,Yoo BS,Cha DH,Jung HO,Ryu DR,Choi JH,Lee KJ,Park TH,Oh JH,Kim SM,Choi JY,Kim KH,Shim J,Kim WS,Choi SW,Park DG,Song PS,Hong TJ,Rhee MY,Rha SW,Park SW

    更新日期:2017-12-01 00:00:00

  • Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.

    abstract:PURPOSE:The goal of this study was to assess the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on lipid profiles in patients with type 2 diabetes. METHODS:The MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched from inception through October 31, 2013. Randomized controll...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.clinthera.2014.11.008

    authors: Sun F,Wu S,Wang J,Guo S,Chai S,Yang Z,Li L,Zhang Y,Ji L,Zhan S

    更新日期:2015-01-01 00:00:00

  • The Cardiac Injury Immune Response as a Target for Regenerative and Cellular Therapies.

    abstract:PURPOSE:Despite modern reperfusion and pharmacologic therapies, myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide. Therefore, the development of further therapeutics affecting post-MI recovery poses significant benefits. This review focuses on the post-MI immune response and immuno...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2020.09.006

    authors: Hume RD,Chong JJH

    更新日期:2020-10-01 00:00:00

  • A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001.

    abstract::A meeting of 14 transplant and pharmacokinetic specialists from Europe and North America was convened in November 2001 to evaluate scientific and clinical data regarding the use of different formulations of cyclosporin A (CsA). The following consensus was achieved. (1) CsA is a critical-dose drug with a narrow therape...

    journal_title:Clinical therapeutics

    pub_type: 共识发展会议,杂志文章,评审

    doi:10.1016/s0149-2918(03)80161-3

    authors: Pollard S,Nashan B,Johnston A,Hoyer P,Belitsky P,Keown P,Helderman H,CONSENT: Consensus on Substitution in European Transplantation.

    更新日期:2003-06-01 00:00:00

  • Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.

    abstract:PURPOSE:Clopidogrel is a thienopyridine prodrug that inhibits platelet aggregation. It is prescribed to prevent atherothrombotic and thromboembolic events in patients receiving a stent implant in carotid, vertebral, or cranial arteries. The influence of cytochrome P-450 (CYP) 2C19 on the response to clopidogrel has bee...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2019.04.037

    authors: Saiz-Rodríguez M,Belmonte C,Caniego JL,Koller D,Zubiaur P,Bárcena E,Romero-Palacián D,Eugene AR,Ochoa D,Abad-Santos F

    更新日期:2019-06-01 00:00:00

  • Ensuring health care quality: a purchaser's perspective--a health care coalition.

    abstract::This paper explores how one health care purchasing coalition in Minnesota, the Buyers Health Care Action Group (BHCAG), has taken an active role in restructuring its local health care market. BHCAG started with the belief that the consumer should be the motivating force in health care delivery. Unfortunately, providin...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Robinow A

    更新日期:1997-11-01 00:00:00

  • Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem.

    abstract:PURPOSE:This article focuses on 10 case studies of companies/organizations that are part of the current innovation ecosystem of regenerative medicine (RM) in the United Kingdom. It analyzes the actors, linkages, and influences that will determine the future shape of the RM industry sector and its capacity to live up to...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2018.06.003

    authors: Banda G,Tait J,Mittra J

    更新日期:2018-07-01 00:00:00

  • Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.

    abstract:BACKGROUND:Desvenlafaxine succinate, a serotonin-norepinephrine reuptake inhibitor (SNRI), was approved by the US Food and Drug Administration (FDA) in February 2008 for the treatment of adult patients with major depressive disorder (MDD). Desvenlafaxine is the third SNRI approved by the FDA for this indication. OBJEC...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2009.07.012

    authors: Perry R,Cassagnol M

    更新日期:2009-06-01 00:00:00

  • Mononitrates: defining the ideal long-acting nitrate.

    abstract::As a result of recent advances in our understanding of the role of nitric oxide and endothelial-derived relaxing factor (EDRF) in vascular control, physicians now have the potential to overcome the loss of EDRF effect by administering nitrates. Nitrates are converted to nitric oxide, resulting in vasodilator effects t...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Frishman WH,Amsterdam E,Glasser SP,Thadani U

    更新日期:1994-03-01 00:00:00

  • Safety and efficacy of feprazone for long-term treatment of rheumatoid arthritis and osteoarthritis.

    abstract::Long-term safety and efficacy of feprazone (4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione), an antirheumatic drug that is well tolerated in the gastrointestinal tract, were assessed in a noncontrolled multicenter trial. Administered at a daily dosage of 600 mg for a mean duration of 114.1 days, feprazone was well tolera...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Bianchi G,Cerri B,Grasso S,Carazzi R,Dotti F,Ongari R,Cerrato O,Viara M

    更新日期:1981-01-01 00:00:00